Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q13268

UPID:
DHRS2_HUMAN

ALTERNATIVE NAMES:
Dicarbonyl reductase HEP27; Protein D; Short chain dehydrogenase/reductase family 25C member 1

ALTERNATIVE UPACC:
Q13268; D3DS54; Q53GS4; Q7Z789; Q9H2R2

BACKGROUND:
The protein Dehydrogenase/reductase SDR family member 2, mitochondrial, known alternatively as Dicarbonyl reductase HEP27, Protein D, and Short chain dehydrogenase/reductase family 25C member 1, functions as a NADPH-dependent oxidoreductase. It is involved in the reduction of dicarbonyl compounds and has shown reductase activity in vitro. The protein's role in attenuating MDM2-mediated p53/TP53 degradation, leading to p53/TP53 stabilization, underscores its significance in cellular processes.

THERAPEUTIC SIGNIFICANCE:
The exploration of Dehydrogenase/reductase SDR family member 2's functions could unveil novel therapeutic avenues. Its involvement in reducing cancer cell proliferation, migration, invasion, and ROS production in cancer suggests a promising potential for cancer therapy development.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.